A case of BRAF mutation‐positive recurrent ovarian high‐grade serous carcinoma with remarkable response to combined dabrafenib and trametinib therapy

Documenti analoghi

• Combination therapy with paclitaxel and trastuzumab for human epidermal growth factor receptor 2‐positive recurrent serous carcinoma of the uterine cervix: A case report
  di: Shizuka Yamada, et al.
  Pubblicazione: (2024)
• CD1a affects the recurrence and prognosis of ovarian cancer
  di: Qiong Zhu, et al.
  Pubblicazione: (2024)
• Diagnosis and management of isolated serous tubal intraepithelial carcinoma: A qualitative focus group study
  di: Serena Negri, et al.
  Pubblicazione: (2024)
• The prevalence of vulvovaginal symptoms in Japanese women of reproductive and perimenopausal ages: A cross‐sectional study across generations
  di: Takao Kawai, et al.
  Pubblicazione: (2024)
• Efficacy of olaparib combined with dabrafenib and trametinib for a patient with BRAF mutated and ATM deleted metastatic melanoma
  di: Theo Marguet, et al.
  Pubblicazione: (2024)